Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+CD25+ regulatory T cell-depleted mice

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8471-8478

  Wei, Wei Zen ^a,c   Jacob, Jennifer B ^a   Zielinski, John F ^a   Flynn, Jeffrey C ^a   Shim, K David ^a   Alsharabi, Ghazwan ^b   Giraldo, Alvaro A ^b   Kong, Yi Chi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; THYROGLOBULIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HASHIMOTO DISEASE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOLOGIC MEMORY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; RECEPTOR, ERBB-2; RECEPTORS, INTERLEUKIN-2; THYROGLOBULIN; THYROIDITIS, AUTOIMMUNE;

EID: 24944551522     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0934     Document Type: Article

References (43)

1. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
2. Woo EY, Yeh H, Chu CS, et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
3. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
4. Wei WZ, Morris GP, Kong YM. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53:73-8.
5. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1-12.
6. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated Antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
7. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S, Aavik E. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-42.
8. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-40.
9. Nakamura K, Kitani A, Striber W. Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med 2001;194:629-44.
10. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
11. Tanchot C, Vasseur F, Pontoux C, Garcia C, Sarukhan A. Immune regulation by self-reactive T cells is antigen specific. J Immunol 2004;172:4285-91.
12. Sakaguchi S. Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors. J Exp Med 2003;197:397-401.
13. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunol 2002;107:5-9.
14. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
15. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
16. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998;1377:M25-37.
17. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 2004;53:166-75.
18. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-8.
19. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of Her-2 in cancer. Oncogene 2003;22:6570-8.
20. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787-94.
21. Sutmuller RPM, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-32.
22. McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003;23:62-72.
23. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7,
24. Morris GP, Chen L, Kong YM. CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 2003;226:20-9.
25. Huang W, Kukes GD. Hashimoto's thyroiditis: an organ-specific autoimmune disease - pathogenesis and recent developments. Lab Invest 1999;79:1175-80.
26. Canonica GW, Cosulich ME, Croci R, et al. Thyroglobulin-induced T-cell in vitro proliferation in Hashimoto's thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens. Clin Immunol Immunopathol 1984;32:132-41.
27. Kong YM, Lomo LC, Motte RW, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med 1996;184:1167-72.
28. Vladutiu AO, Rose NR. Autoimmune murine thyroiditis: relation to histocompatibility (H-2) type. Science 1971;174:1137-9.
29. Esquivel PS, Rose NR, Kong YM. Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide. J Exp Med 1977;145:1250-63.
30. ElRehewy M, Kong YM, Giraldo AA, Rose NR. Syngeneic thyroglobulin is immunogenic in good responder mice. Eur J Immunol 1981;11:146-51.
31. Kong YM, Okayasu I, Giraldo AA, et al. Tolerance to thyroglobulin by activating suppressor mechanisms. Ann N Y Acad Sci 1982;392:191-209.
32. Mahoney KH, Miller BE, Heppner GH. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J Leukocyte Biol 1985;38:573-85.
33. Rovero S, Amici A, Di Carlo E, et al. Inhibition of carcinogenesis by DNA vaccination. J Immunol 2000;165:5133-42.
34. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.
35. Piechocki MP, Pilon S, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 2002;259:33-42.
36. Kong YM. Experimental autoimmune thyroiditis in the mouse. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York: John Wiley & Sons, Inc.; 1996. p. 15.7.1-15.7.16.
37. Kong YM, David CS, Giraldo AA, Elrehewy M, Rose NR. Regulation of autoimmune response to mouse thyroglobulin: influence of H-2D-end genes. J Immunol 1979;123:15-8.
38. Zhang W, Flynn JC, Kong YM. IL-12 prevents tolerance induction with mouse thyroglobulin by priming pathogenic T cells in experimental autoimmune thyroiditis: role of IFN-γ and the costimulatory molecules CD40L and CD28. Cell Immunol 2001;208:52-61.
39. Medina D, DeOme KB. Effects of various oncogenic agents on the tumor-producing capabilities of the D series of BALB/c mammary nodule outgrowth lines. J Nat Cancer Inst 1970;45:353-63.
40. Conaway DH, Giraldo AA, David CS, Kong YM. In situ kinetic analysis of thyroid lymphocyte infiltrate in mice developing experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1989;53:346-53.
41. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines and perform for the immune eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111:1161-70.
42. Pilon SA, Kelly C, Wei WZ. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 2003;170:1202-8.
43. Lindencrona JA, Preiss S, Kammertoens T, et al. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004;109:259-64.